Alexanian R, Barlogie B, Fritsche H
Am J Hematol. 1985 Dec;20(4):345-51. doi: 10.1002/ajh.2830200405.
Serum beta 2 microglobulin levels (B2M) were evaluated before and during chemotherapy in 97 previously untreated patients with multiple myeloma. Pretreatment values were useful in confirming tumor mass grade, and marked reductions following chemotherapy correlated well with the onset of remission. No gain was evident from correcting the B2M for the level of serum creatinine. A pretreatment B2M value greater than 6 mg/L correlated with a low response rate and was the most important variable that predicted a short survival time.
对97例既往未接受过治疗的多发性骨髓瘤患者在化疗前及化疗期间评估了血清β2微球蛋白水平（B2M）。治疗前的值有助于确认肿瘤肿块分级，化疗后明显降低与缓解的开始密切相关。校正血清肌酐水平后的B2M未显示出明显优势。治疗前B2M值大于6mg/L与低缓解率相关，是预测生存期短的最重要变量。
